Glenmark Pharmaceuticals Desmopressin Acetate Tablets Recall

Why it was recalled

CGMP Deviations

Product description

Desmopressin Acetate Tablets, 0.2 mg, 100-count bottles, Rx Only, Manufactured for: Northstar Rx LLC, Memphis, TN 38141, Manufactured by: Glenmark Pharmaceuticals Ltd., Colvale-Bardez, Goa 403513, India, NDC 16714-884-01

Lot numbers, UPCs & expiration codes

Lot #: 20020121, Exp 01/2024

Where it was sold

One sole distributor in TX

What to do if you have this product

Compare the lot number and expiration date on your package with the codes above.
Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
If you have symptoms you think are related, contact your doctor. In an emergency call 911.
Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number: D-1171-2022
Classification: Class II
Status: Terminated
Recall initiated: Jun 29, 2022
FDA report date: Jul 6, 2022
Quantity: 36 bottles
Recall type: Voluntary: Firm initiated
Recalling firm: Glenmark Pharmaceuticals Inc., USA

Original FDA data

Every field from FDA enforcement report D-1171-2022, exactly as published.

Show all FDA fields

City: Mahwah
State: NJ
Status: Terminated
Country: United States
Event ID: 90431
Address: 750 Corporate Dr
Code information: Lot #: 20020121, Exp 01/2024
Postal code: 07430-2009
Report date: Jul 6, 2022
Product type: Drugs
Recall number: D-1171-2022
Classification: Class II
Recalling firm: Glenmark Pharmaceuticals Inc., USA
Product quantity: 36 bottles
Termination date: Jun 23, 2023
Reason for recall: CGMP Deviations
Voluntary / mandated: Voluntary: Firm initiated
Product description: Desmopressin Acetate Tablets, 0.2 mg, 100-count bottles, Rx Only, Manufactured for: Northstar Rx LLC, Memphis, TN 38141, Manufactured by: Glenmark Pharmaceuticals Ltd., Colvale-Bardez, Goa 403513, India, NDC 16714-884-01
Distribution pattern: One sole distributor in TX
Recall initiation date: Jun 29, 2022
Initial firm notification: Letter
Center classification date: Jun 30, 2022

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1171-2022, published Jul 6, 2022. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: Oct 2, 2026. Content last changed: Oct 2, 2026.

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.